Research progress on alpha-2-macroglobulin and its glycosylation in tumor

doi:10.3969/j.issn.1673-8640.2017.010.020

Abstract

Abstract:

Alpha-2-macroglobulin（α₂-MG） is the largest protein in plasma,which is synthesized by liver cells and mononuclear macrophage system. Human α₂-MG is a homotetramer comprised of 4 same subunits. As a broad spectrum protease inhibitor in plasma,α₂-MG is involved in the pathophysiology of many diseases. In this review,the structure and function of α₂-MG and its glycosylation are briefly expounded. The research progress on the relationship of α₂-MG with liver cancer and other common malignant tumors are reviewed,as well as the research progress on the relationship between α₂-MG glycosylation and carcinogensis.

Key words: Alpha-2-macroglobulin, Serum marker, Glycoprotein, Protease inhibitor, Glycosylation, Tumor

CLC Number:

R446.1

ZHAN Xianlin, YAN Wei, GAO Chunfang. Research progress on alpha-2-macroglobulin and its glycosylation in tumor[J]. Laboratory Medicine, 2017, 32(10): 922-927.

References 40

[1]	BAKER A H,EDWARDS D R,MURPHY G.Metalloproteinase inhibitors:biological actions and therapeutic opportunities[J]. J Cell Sci,2002,115(Pt 19):3719-3727.
[2]	REHMAN A A,AHSAN H,KHAN F H.Identification of a new alpha-2-macroglobulin:multi-spectroscopic and isothermal titration calorimetry study[J]. Int J Biol Macromol,2016,83:366-375.
[3]	皇甫超济,吕茂民,马玉媛,等. α2-巨球蛋白活性检测方法的建立与优化[J]. 军事医学,2015,60(3):193-195.
[4]	PAIVA M M,SOEIRO M N,BARBOSA H S,et al.Glycosylation patterns of human alpha2-macroglobulin:analysis of lectin binding by electron microscopy[J]. Micron,2010,41(6):666-673.
[5]	LIN Z,LO A,SIMEONE D M,et al.An N-glycosylation analysis of human alpha-2-macroglobulin using an integrated approach[J]. J Proteomics Bioinform,2012,5:127-134.
[6]	PANZIRONI C,SILVESTRINI B,MO M Y,et al.An increase in the carbohydrate moiety of alpha 2-macroglobulin is associated with systemic lupus erythematosus(SLE)[J]. Biochem Mol Biol Int,1997,43(6):1305-1322.
[7]	皇甫超济,吕茂民,马玉媛,等. α2-巨球蛋白的特性与功能[J]. 中国输血杂志,2016,29(2):217-222.
[8]	BORTH W.Alpha 2-macroglobulin,a multifunctional binding protein with targeting characteristics[J]. FASEB J,1992,6(15):3345-3353.
[9]	CHEN X,KONG X,ZHANG Z,et al.Alpha-2-macroglobulin as a radioprotective agent:a review[J]. Chin J Cancer Res,2014,26(5):611-621.
[10]	LEGRES L G,POCHON F,BARRAY M,et al.Human alpha 2-macroglobulin as a cytokine-binding plasma protein. A study with rh-interleukin-1 beta and rh-interleukin-6[J]. Ann N Y Acad Sci,1994,737:439-443.
[11]	SATO M,YAO V J,ARAP W,et al.GRP78 signaling hub a receptor for targeted tumor therapy[J]. Adv Genet,2010,69:97-114.
[12]	CARVALHO S,TROOST E G,BONS J,et al.Prognostic value of blood-biomarkers related to hypoxia,inflammation,immune response and tumour load in non-small cell lung cancer-a survival model with external validation[J]. Radiother Oncol,2016,119(3):487-494.
[13]	KIM J H,KIM Y W,KIM I W,et al.Identification of candidate biomarkers using the ExperionTM automated electrophoresis system in serum samples from ovarian cancer patients[J]. Int J Oncol,2013,42(4):1257-1262.
[14]	MAZOUNI C,BAGGERLY K,HAWKE D,et al.Evaluation of changes in serum protein profiles during neoadjuvant chemotherapy in HER2-positive breast cancer using an LC-MALDI-TOF/MS procedure[J]. Proteomics,2010,10(19):3525-3532.
[15]	SUNDERIC M,SEDIVA A,ROBAJAC D,et al.Lectin-based protein microarray analysis of differences in serum alpha-2-macroglobulin glycosylation between patients with colorectal cancer and persons without cancer[J]. Biotechnol Appl Biochem,2016,63(4):457-464.
[16]	LIN Z,YIN H,LO A,et al.Label-free relative quantification of alpha-2-macroglobulin site-specific core-fucosylation in pancreatic cancer by LC-MS/MS[J]. Electrophoresis,2014,35(15):2108-2115.
[17]	KUROKAWA Y,MATOBA R,TAKEMASA I,et al.Molecular features of non-B,non-C hepatocellular carcinoma:a PCR-array gene expression profiling study[J]. J Hepatol,2003,39(6):1004-1012.
[18]	KAR P,GANDHI B M,IRSHAD M,et al.Alpha-2 macroglobulin: an additional marker for diagnosis of hepatocellular carcinoma[J]. J Assoc Physicians India,1987,35(4):288-289.
[19]	李丽. 岩藻糖基化修饰蛋白在原发性肝细胞癌中的研究进展[J]. 检验医学,2012,27(4):324-328.
[20]	POON T C,CHAN A T,ZEE B,et al.Application of classification tree and neural network algorithms to the identification of serological liver marker profiles for the diagnosis of hepatocellular carcinoma[J]. Oncology,2001,61(4):275-283.
[21]	SUKATA T,UWAGAWA S,OZAKI K,et al.Alpha(2)-macroglobulin: a novel cytochemical marker characterizing preneoplastic and neoplastic rat liver lesions negative for hitherto established cytochemical markers[J]. Am J Pathol,2004,165(5):1479-1488.
[22]	NOMURA F,OHNISHI K,TANABE Y.Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients[J]. Cancer,1989,64(8):1700-1707.
[23]	ZHAO S,LI H,WANG Q,et al.The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M[J]. BMC Cancer,2015,15:389.
[24]	JEMAL A,SIEGEL R,WARD E,et al.Cancer statistics,2008[J]. CA Cancer J Clin,2008,58(2):71-96.
[25]	VISINTIN I,FENG Z,LONGTON G,et al.Diagnostic markers for early detection of ovarian cancer[J]. Clin Cancer Res,2008,14(4):1065-1072.
[26]	SHIELD-ARTIN K L,BAILEY M J,OLIVA K,et al. Identification of ovarian cancer-associated proteins in symptomatic women:a novel method for semi-quantitative plasma proteomics[J]. Proteomics Clin Appl,2012,6(3-4):170-181.
[27]	KANOH Y,OHTANI N,MASHIKO T,et al.Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer[J]. Anticancer Res,2001,21(1B):551-556.
[28]	PARTIN A W,YOO J,CARTER H B,et al.The use of prostate specific antigen,clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer[J]. J Urol,1993,150(1):110-114.
[29]	KANOH Y,OHTANI H,KOSHIBA K.Studies on alpha 2 macroglobulin deficiency in association with cancer metastasis[J]. Nihon Rinsho Meneki Gakkai Kaishi,1997,20(1):30-43.
[30]	LIEDTKE C,MAZOUNI C,HESS K R,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J]. J Clin Oncol,2008,26(8):1275-1281.
[31]	CHO W C,CHENG C H.Oncoproteomics: current trends and future perspectives[J]. Expert Rev Proteomics,2007,4(3):401-410.
[32]	PUSZTAI L,GREGORY B W,BAGGERLY K A,et al.Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma[J]. Cancer,2004,100(9):1814-1822.
[33]	CARVALHO S,TROOST E G,BONS J,et al.Prognostic value of blood-biomarkers related to hypoxia,inflammation,immune response and tumour load in non-small cell lung cancer-a survival model with external validation[J]. Radiother Oncol,2016,119(3):487-494.
[34]	SIMONE C N 2nd,BURRI S H,HEINZERLING J H. Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies[J]. Transl Lung Cancer Res,2015,4(5):545-552.
[35]	BRAOUDAKI M,LAMBROU G I,VOUGAS K,et al.Protein biomarkers distinguish between high- and low-risk pediatric acute lymphoblastic leukemia in a tissue specific manner[J]. J Hematol Oncol,2013,6:52.
[36]	CAVALCANTE MDE S,TORRES-ROMERO J C,LOBO M D,et al. A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia[J]. Biomark Res,2016,4:1.
[37]	LUO Y,DENG Z,CHEN J.Pivotal regulatory network and genes in osteosarcoma[J]. Arch Med Sci,2013,9(3):569-575.
[38]	NIU F,ZHAO S,XU C Y,et al.Identification and functional analysis of differentially expressed genes related to metastatic osteosarcoma[J]. Asian Pac J Cancer Prev,2015,15(24):10797-10801.
[39]	CLERC F,REIDING K R,JANSEN B C,et al.Human plasma protein N-glycosylation[J]. Glycoconj J,2016,33(3):309-343.
[40]	DUBE D H,BERTOZZI C R.Glycans in cancer and inflammation-potential for therapeutics and diagnostics[J]. Nat Rev Drug Discov,2005,4(6):477-488.